Dunn, R. Targeting Novel B-Cell Antigens with CAR T-Cells in Plasma Cell Malignancies. Asia Pacific Cell and Gene Therapy Conference. September 2025.
Keywords: Immunotherapies | Blood Cancer | | B-Cell | CAR T cells | Multiple Myeloma | Haematological Malignancies
Mary Sartor, Thomas X Lemarchand, Luise Britz, Jeremy Erc, Simon J Harrison, Rosanne Dunn and David J Gottlieb. Novel therapeutic targets Kappa myeloma antigen (KMA) and Lambda myeloma antigen (LMA) are expressed on malignant plasma cells from patients with plasma cell dyscrasias but not on normal plasma cells. International Myeloma Society, Toronto, Canada. September 2025.
Keywords: KappaMab | LambdaMab | | KMA | LMA | Plasma Cell Dyscrasias | Multiple Myeloma
Sartor, M., Gottlieb, D., and Dunn, R. Novel antigens LMA and KMA are expressed on malignant bone marrow plasma cells from patients at all stages of multiple myeloma and in other plasma cell dyscrasias. International Myeloma Society, Athens, Greece, October 2023
Keywords: KMA | LMA | Plasma Cell Dyscrasias | KappaMab |10B3 | 7F11 | LambdaMab
Dunn, R. Specificity of KMA.CAR T cells against a novel B cell target called kappa myeloma antigen (KMA). IMAPAC - World Asia Biologics Contract Manufacturing Conference, Singapore, 14-15 September 2023
Keywords: KMA | KMA.CAR-T cell | non-clinical data
Li J, Haynes N, Cummins K, et al. Cellular Immunotherapy Targeting Kappa Myeloma Antigen for the Treatment of Multiple Myeloma. Cancer Res. 2023; 83 (7_Supplement): 4074.
Keywords: Kappa Myeloma Antigen | KMA.CAR T Cells | In Vitro | In Vivo | Multiple Myeloma
Sartor, M., Dunn, R., and Gottlieb, D.J. Kappa myeloma antigen (KMA) and Lambda myeloma antigen (LMA) are expressed on B cell malignancies and are promising novel targets on malignant plasma cells. Hematol Oncol. 2023; 41(S2): 776-777.
Keywords: KappaMab | LambdaMab | Plasma Cell Dyscrasias | KMA | LMA | Multiple Myeloma
Harrison, S, Li J, Haynes N, et al. Lentiviral generation of CAR-T cells targeting kappa myeloma antigen for the treatment of multiple myeloma. Myeloma Australia 4th National Myeloma Workshop Event; Pathways to a Cure. 21-23 October 2022. Kalorama, Victoria, Australia.
Keywords: Kappa Myeloma Antigen | KMA.CAR T Cells | In Vitro | In Vivo | Multiple Myeloma
Sartor, M., Dunn, R., and Gottlieb, D.J. Expression of kappa myeloma antigen (KMA) and lambda myeloma antigen (LMA) on bone marrow plasma cells in patients with multiple myeloma: implications for antibody and cellular therapy. Myeloma Australia 4th National Myeloma Workshop Event; Pathways to a Cure. 21-23 October 2022. Kalorama, Victoria, Australia.
Keywords: KappaMab | LambdaMab | Plasma Cell Dyscrasias | Multiple Myeloma | KMA | LMA
Sartor, M., Gottlieb, DJ., and Dunn, R. Novel Antigens LMA and KMA are Expressed on Malignant Bone Marrow Plasma Cells from Patients with Relapsed Refractory Multiple Myeloma and Plasma Cell Dyscrasias. Blood. 2022; 140 (Supplement 1): 4211–4212.
Keywords: KappaMab | LambdaMab | Plasma Cell Dyscrasias | Multiple Myeloma | KMA | LMA
Sartor, M., Hu, D., Lemarchand, T.X., et al. A Novel B Cell Antigen Designated Lambda Myeloma Antigen (LMA) Has Been Identified Using Two Fully Human Monoclonal Antibodies (Mabs) That Bind to Similar Epitopes on Plasma Cells from Patients with Plasma Cell Dyscrasias. Blood. 2021; 138 (Supplement 1):1595.
Keywords: KappaMab | LambdaMab | Plasma Cell Dyscrasias | 10B3 | 7F11
Kalff, A., Shortt, J., Yuen, F., et al. A sequential cohort study comparing KappaMab alone to KappaMab, lenalidomide and low dose dexamethasone in kappa-restricted relapsed refractory (RR) multiple myeloma (AMaRC 01-16). Blood. 2019; 134 (Supplement 1): 3144.
Keywords: KappaMab | Clinical Trial | Kappa-type multiple myeloma | Lenalidomide
Gowrishankar, K., Dunn, R., Gottlieb, D., and Micklethwaite, K. CAR T-cells targeting the kappa myeloma antigen for the treatment of multiple myeloma. Cancer Res. 2018; 78 (13_Supplement):3572.
Keywords: CAR T cells | Kappa-type multiple myeloma
Cuddihy, A. R., Khong, Asvadi, P., et al. HDACi and IMiDs enhance anti-myeloma activity of the anti-KMA monoclonal antibody MDX-1097. Clin Lymph Myel Leuk. 2013; 13(supplement 1): P-281.
Keywords: KappaMab | MDX-1097 | ADCC
Asvadi, P., Jennings, C., Jiang, V., et al. Identification and characterization of lambda myeloma antigen, LMA, as a therapeutic target in lambda type multiple myeloma. Haematologica. 2013; 98(s1):756.
Keywords: Lambda-type multiple myeloma | LMA
Dunn, R., Spencer, A., Augustson B., et al. Phase 2a, open-label, multi-dose study of the anti-kappa monoclonal antibody, MDX-1097, in relapsed kappa-chain restricted multiple myeloma with stable measurable disease. Haematologica. 2013; 98(s1):776.
Keywords: KappaMab / MDX-1097 | Clinical Trial | Kappa-type multiple myeloma KMA
Cuddihy, A.R., Khong, T., Dunn, R., et al. The anti-kappa monoclonal antibody MDX-1097 synergizes with immunomodulatory drugs to enhance antibody-dependent cell cytotoxicity of multiple myeloma cells. Blood. 2012; 120 (21): 4012.
Keywords: KappaMab / MDX-1097 | In vitro | ADCC / Apoptosis
Cuddihy, A.R., Khong, T., Dunn, R., et al. The anti-kappa monoclonal antibody MDX-1097 cooperates with lenalidomide to enhance antibody-dependent cell cytotoxicity of multiple myeloma cells.
Cancer Res. 2012; 72 (8_Supplement): 2522.
Keywords: KappaMab / MDX-1097 | In vitro | ADCC / Apoptosis | Lenalidomide
Spencer, A., Walker, P., Asvadi, P., et al. A phase I study of the anti-kappa monoclonal antibody, MDX-1097, in previously treated multiple myeloma patients. J Clin Oncol. 2010; 28(15_suppl):8143.
Keywords: KappaMab / MDX-1097 | Clinical Trial | Kappa-type multiple myeloma / KMA
Alexova, R., Hutchinson, A., Jones, D.R., et al. Characterisation of a novel conformational epitope on human free kappa light chains defined by a monoclonal antibody with therapeutic potential for multiple myeloma. The Australian and New Zealand Society for Immunology meeting. Sydney Australia, 2007.
Keywords: Free light chains | K-1-21 or mKap | Epitope
Raison, R.L., Jones, D.R., Asvadi, P., et al. A chimeric monoclonal antibody specific for kappa multiple myeloma plasma cells mediates ADCC of tumor cells. Haematologica. 2005; 90(s1) PO-206.
Keywords: K-1-21 or mKap | In vivo model
Asvadi, P., Jones, D.R., Dunn, R., et al. A monoclonal antibody specific for free human kappa light chains induces apoptosis of multiple myeloma cells and exhibits anti-tumor activity in vivo. Blood. 2004; 104(11): 2416.
Keywords: K-1-21 or mKap | In vivo model | ADCC / Apoptosis